Asp Isotopes INC 8-K filings

ASP Isotopes Inc. announced a four-year supply agreement with Isotopia Molecular Imaging Ltd. for enriched Gadolinium-160, a critical precursor for advanced cancer therapies, alongside plans for an investor access event in South Africa.

ASP Isotopes Inc. announced the pricing of an underwritten registered direct offering of 7,518,797 shares of its common stock at $6.65 per share, expecting to raise approximately $46.8 million in net proceeds for general corporate purposes and a bridge loan to Renergen.

ASP Isotopes Inc. has announced a series of significant milestones, including new production capabilities, key partnerships with TerraPower for nuclear fuel, and a proposed acquisition of Renergen Limited to create a global critical materials powerhouse.

ASP Isotopes Inc. announced it has raised approximately $4.9 million in gross proceeds from the exercise of warrants by Armistice Capital Master Fund Ltd. and another warrant holder, resulting in the issuance of 1,294,778 shares of common stock.

ASP Isotopes Inc. has formalized its intention to acquire South African energy company Renergen Limited, a transaction valued at approximately $110 million, despite Renergen facing material uncertainties regarding its going concern status, loan defaults, and a substantial increase in its annual loss.

ASP Isotopes Inc. announces a $22 million loan agreement with TerraPower to partially finance a uranium enrichment facility for High Assay Low-Enriched Uranium (HALEU) production.

ASP Isotopes Inc. announces a definitive agreement to acquire Renergen Limited, aiming to establish a global leader in critical materials production.

ASP Isotopes has entered into definitive agreements with TerraPower, including a loan agreement to support the construction of a uranium enrichment facility and supply agreements for High Assay Low-Enriched Uranium (HALEU).

ASP Isotopes announces the appointment of Sipho Maseko to its board, the transition of Dr. Hendrik Strydom to Quantum Leap Energy LLC's board, and plans to separate its nuclear fuels business in 2H 2025.

ASP Isotopes Inc. has successfully commissioned its first Quantum Enrichment laser system and begun producing commercial samples of Ytterbium-176, a critical material for oncology treatments.

ASP Isotopes Inc. will release its fourth quarter and fiscal year 2024 financial results and host a webinar to discuss the results and future strategies.

ASP Isotopes has begun commercial production of enriched Silicon-28 at its second facility, anticipating shipments in Q2 2025 and aiming to serve the quantum computing and next-generation semiconductor industries.

ASP Isotopes announces the start of commercial production of enriched Carbon-14 at its first Aerodynamic Separation Process (ASP) enrichment facility.

ASP Isotopes reports significant advancements in its isotope production capabilities, including exceeding enrichment factor expectations and accelerating facility commissioning timelines.

ASP Isotopes reports significant progress in 2024, including the completion of multiple enrichment facilities and securing key contracts, while outlining ambitious goals for 2025.

ASP Isotopes has issued a statement refuting a short seller report, defending its technology and strategic initiatives, and reaffirming its commitment to growth.

ASP Isotopes will host an investor access event in South Africa from January 14-16, 2025, to showcase its isotope enrichment facilities.

ASP Isotopes has issued a statement refuting claims made in a short seller report, reaffirming its technology and growth prospects.

ASP Isotopes has completed the construction of its Silicon-28 enrichment facility and has commenced the commissioning phase, with commercial deliveries expected in the first half of 2025.

ASP Isotopes Inc. held its 2024 Annual Meeting of Stockholders on November 20, 2024, where stockholders voted on the election of directors, approval of an equity incentive plan, and ratification of the company's accounting firm.

ASP Isotopes Inc. has signed a Memorandum of Understanding with the South African Nuclear Energy Corporation to collaborate on the research, development, and commercial production of advanced nuclear fuels.

ASP Isotopes successfully closed its public offering, raising $18.6 million after the underwriter fully exercised its option to purchase additional shares.

ASP Isotopes has successfully priced a public offering of common stock, expected to generate approximately $17.1 million in net proceeds.

ASP Isotopes has entered into a term sheet with TerraPower to potentially fund and construct a uranium enrichment facility for producing High Assay Low-Enriched Uranium (HALEU), followed by a 10-year supply agreement.

ASP Isotopes has successfully enriched Ytterbium-176 during the commissioning of its first quantum enrichment facility, significantly ahead of the initial timeline, and anticipates commercial sales in 2025.

Quantum Leap Energy LLC has amended its 2024 Equity Incentive Plan, reducing the maximum number of shares issuable from 30% to 15% of outstanding common equity.

ASP Isotopes Inc. has completed the construction phase of its Ytterbium-176 enrichment plant nine months ahead of schedule, potentially easing supply chain constraints in the growing radiopharmaceutical market.

ASP Isotopes successfully closed its public offering, raising $34.5 million through the sale of 13.8 million shares, including the full exercise of the underwriter's option.

ASP Isotopes has priced a public offering of 12 million shares of common stock at $2.50 per share, aiming to raise $30 million before expenses.

ASP Isotopes Inc. has appointed Heather Kiessling as its new Chief Financial Officer, effective July 1, 2024, to support the company's next phase of growth.